Clinical trial
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable…
NCT00393068 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00393068 |
|---|---|
| Title | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer |
| Official title | A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Erlotinib, Bevacizumab, Paclitaxel, Carboplatin, 5-FU, Radiation therapy, Surgery |
| Enrollment | 62 |
| Start date | Feb 1, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Aug 1, 2011 |
| First posted | Oct 26, 2006 |
| Last update posted | Mar 2, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: